Piramal Pharma Solutions (PPS) is spending $55 million across its sites in North America and Asia to expand its API manufacturing capacities and capabilities.

“With these investments, we can now support the  commercialization of our pipeline of over 80 programs that are at Phase II or beyond, while allowing us additional capacity for future partnerships,” said CEO  Vivek Sharma.

The Indian contract manufacturer will spend part of the investment on new multi-purpose plants, totalling more than 270,000 liters, to support its late-stage programs.

In addition, PPS will expand potency capability at its plant in Riverview, Michigan, USA, to a new occupational exposure limit of ≥10 ng/m³, and add GMP kilo laboratories and a pilot plant in Ennore, India, to increase its early development capabilities.

In Morpeth, UK, PPS will increase early development capabilities in both drug substances and drug products to better serve its European biotech customers.

Support functions such as analytical capabilities, R&D infrastructure, automation and IT systems will also be expanded at all API sites.